Imatinib Amarox (Imatinib)

Imatinib targets BCR‑ABL and other tyrosine kinases and is indicated for several malignancies.

• Chronic Myeloid Leukemia (CML): inhibits leukemic cell proliferation and induces remission.
• Gastrointestinal Stromal Tumor (GIST): provides disease control by blocking KIT signaling.
• Philadelphia‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): contributes to achieving complete remission.

• Imatinib binds competitively to the ATP‑binding pocket of BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This blockade halts the signaling cascades that drive uncontrolled cell division, leading to reduced tumor growth and increased apoptosis of malignant cells.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Edema: swelling of the extremities, especially ankles.
• Muscle cramps: intermittent tightening of muscles.
• Fatigue: generalized tiredness.
• Diarrhea: loose stools.
• Rash: mild skin irritation.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Severe neutropenia: marked reduction in white blood cells.
• Cardiac failure: reduced heart pumping ability.
• Pulmonary hypertension: increased pressure in lung arteries.
• Stevens‑Johnson syndrome: severe skin and mucous membrane reaction.
• Hemorrhage: abnormal bleeding events.

Patients should be monitored closely for safety concerns.

• Blood count monitoring: perform regular CBC to detect cytopenias.
• Liver function testing: assess hepatic enzymes before and during therapy.
• Cardiac assessment: evaluate baseline and periodic cardiac function.
• Hypersensitivity avoidance: discontinue if severe allergic reaction occurs.
• Pregnancy caution: use only if benefits outweigh potential fetal risks.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Imatinib may interact with several concomitant medicines.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase imatinib exposure.
• Strong CYP3A4 inducers (e.g., rifampin): reduce imatinib effectiveness.
• Antacids containing aluminum or magnesium: decrease oral absorption.
• Warfarin: may potentiate anticoagulant effect and raise INR.
• QT‑prolonging agents: heighten risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Digoxin: possible increase in serum levels.
• NSAIDs: may enhance bleeding tendency.
• Live vaccines: reduced efficacy; consider timing of vaccination.